Mirati Therapeutics Says EMA's CHMP Issued Negative Opinion On Conditional Marketing Authorisation Application For KRAZATI (Adagrasib) For Patients With KRASG12C -Mutated Advanced Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Mirati Therapeutics has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on its application for conditional marketing authorization for KRAZATI (Adagrasib) for patients with KRASG12C-mutated advanced non-small cell lung cancer. Mirati disagrees with the opinion and plans to request a formal re-examination.
July 21, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirati Therapeutics' stock may be negatively impacted in the short term due to the negative opinion from EMA's CHMP on its application for KRAZATI (Adagrasib).
The negative opinion from EMA's CHMP on Mirati's application for KRAZATI (Adagrasib) is a significant setback for the company. This could lead to a delay in the drug's approval and potential revenue generation, which could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100